Paper30763536
Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria.
Kortright KE and 3 others. Cell Host Microbe, 2019. Cited by 899 papers, by iCite.
Cite this record
ConductScience Library. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Papers, record 30763536. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30763536
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics4
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bacterial Infections | Major topic |
| Phage Therapy | Major topic |
| Biomedical Research | |
| Humans |
Source PubMed
Cited by691
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 899 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42973455 | Clinical improvement despite rising anti-streptococcal antibody titers during adjunctive bacteriophage therapy in refractory PANDAS: a hypothesis-generating case report. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/42973455 | PubMed |
| 42961713 | Phage therapy for bacterial infections of CNS: a pharmacotherapeutic perspective. | Folia Microbiol (Praha) | 2026 | https://conductscience.org/library/papers/42961713 | PubMed |
| 42959903 | Biological and genomic characterization of Escherichia phage KBU_SV1 active against carbapenem-resistant Escherichia coli. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42959903 | PubMed |
| 42944064 | Phage Receptor-Binding Proteins for Targeted Silver Nanoparticle Delivery: Design and Evaluation. | Viruses | 2026 | https://conductscience.org/library/papers/42944064 | PubMed |
| 42943547 | Surveillance, Detection and Therapeutic Innovation in Antimicrobial Resistance in the Age of Polycrisis: From Genomic and Digital Innovation to One Health Integration. | Microorganisms | 2026 | https://conductscience.org/library/papers/42943547 | PubMed |
| 42943513 | Bacteriophage Therapy for Aeromonas salmonicida: A Systematic Evaluation of Translational Readiness in Aquaculture. | Microorganisms | 2026 | https://conductscience.org/library/papers/42943513 | PubMed |
| 42939852 | Interplay Between the Gut Microbiome and Oxidative Stress in Type 2 Diabetes. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42939852 | PubMed |
| 42939211 | Salmonella Phage X5 Alleviates Salmonella pullorum-Induced Growth Impairment in Chickens: Associations with Reduced Salmonella Burden, Modulated Intestinal Microbiome and Attenuated Inflammatory Responses. | Animals (Basel) | 2026 | https://conductscience.org/library/papers/42939211 | PubMed |
| 42938691 | Shared Resistance, Phage-Receptor, and Biofilm Determinants in Antibiotic-Resistant Pseudomonas aeruginosa, Escherichia coli, and Acinetobacter baumannii: A Bibliometric and Gene-Network Analysis of Phage Cocktail Research. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42938691 | PubMed |
| 42931219 | Targeting Multidrug-Resistant Pseudomonas aeruginosa from Companion Animals Using Bacteriophages. | Pathogens | 2026 | https://conductscience.org/library/papers/42931219 | PubMed |
| 42930062 | Phenotypic Characterization and Preliminary In Vivo Evaluation of a Locally Isolated Klebsiella pneumoniae Bacteriophage. | BioTech (Basel) | 2026 | https://conductscience.org/library/papers/42930062 | PubMed |
| 42920789 | Antibiotic resistance genes in aquaculture: Molecular detection, environmental dynamics, and biological control strategies. | iScience | 2026 | https://conductscience.org/library/papers/42920789 | PubMed |
| 42903523 | Personalized bacteriophage therapy for chronic biliary tract Pseudomonas aeruginosa infections. | Hlife | 2025 | https://conductscience.org/library/papers/42903523 | PubMed |
| 42899184 | Phage Therapy as a Self-Replicating Strategy for Besieged Health Systems. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42899184 | PubMed |
| 42898560 | Gut microbiome-shaped chemotherapy responses across cancer types: mechanisms of resistance, biomarkers, and targeted interventions. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898560 | PubMed |
| 42859560 | Gut microbiota dysbiosis: Pathogenic drivers and emerging phage-based therapeutics. | AIMS Microbiol | 2026 | https://conductscience.org/library/papers/42859560 | PubMed |
| 42850340 | The bacteriophage transcription factor Gp53 suppresses cell division and regulates Pseudomonas aeruginosa physiology. | Commun Biol | 2026 | https://conductscience.org/library/papers/42850340 | PubMed |
| 42827202 | A dual-action bacteriophage protein Ped1 degrades DNA and blocks replication in Pseudomonas aeruginosa. | EMBO J | 2026 | https://conductscience.org/library/papers/42827202 | PubMed |
| 42811102 | Phylogeny-agnostic strain-level prediction of phage-host interactions from genomes using machine learning. | Nat Microbiol | 2026 | https://conductscience.org/library/papers/42811102 | PubMed |
| 42797510 | Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42797510 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30763536
GET https://conductscience.org/api/papers/v1/30763536/cited_by?page=2